1.5003

2.55% +0.0203

TC BioPharm (Holdings) plc ADR (TCBP)

Overview News Price History Discussions Forecast Stock Split

TC BioPharm (Holdings) plc ADR stock is currently priced at $1.5003, with a 24-hour trading volume of 6,076. It has seen a +2.55% increased in the last 24 hours and a +19.51% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.48 pivot point. If it approaches the $1.53 resistance level, significant changes may occur.

Previous Close:

$1.48

Open:

$1.47

24h Volume:

6,076

Market Cap:

$4.73M

Revenue:

$4.60M

Net Income/Loss:

$-7.33M

P/E Ratio:

0.0323

EPS:

46.49

Net Cash Flow:

$-13.42M

1W Performance:

-3.32%

1M Performance:

+19.51%

6M Performance:

-82.98%

1Y Performance:

-92.84%

1D Range:

$1.47

$1.4801

52W Range:

$0.8501

$26.60

TC BioPharm (Holdings) plc ADR Stock (TCBP) Company Profile

Name

TC BioPharm (Holdings) plc ADR

Sector

Healthcare (1193)

Industry

Biotechnology (685)

Phone

44 14 1433 7557

Address

Maxim 1, 2 Parklands Way Holytown, Motherwell

Employee

Twitter

Next Earnings Date

Latest SEC Filings

TCBP's Discussions on Twitter

TC BioPharm (Holdings) plc ADR Stock (TCBP) Latest News

Green Flags to Look for in a Penny Stock

PennyStocks

Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket

Benzinga

Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results

Benzinga

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings

Benzinga

Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000

Benzinga

TC BioPharm (Holdings) plc ADR Stock (TCBP) Financials Data

TC BioPharm (Holdings) plc ADR (TCBP) Revenue 2024

TCBP reported a revenue (TTM) of $4.60 million for the quarter ending December 31, 2022.

TC BioPharm (Holdings) plc ADR (TCBP) Net Income 2024

TCBP net income (TTM) was -$7.33 million for the quarter ending December 31, 2023.

TC BioPharm (Holdings) plc ADR (TCBP) Cash Flow 2024

TCBP recorded a free cash flow (TTM) of -$13.42 million for the quarter ending December 31, 2023.

TC BioPharm (Holdings) plc ADR (TCBP) Earnings per Share 2024

TCBP earnings per share (TTM) was -$5.0566 for the quarter ending December 31, 2023.

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.